Xamoterol
Cardiac stimulant drug
- C01CX07 (WHO)
- (RS)-N-(2-{[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino}ethyl)morpholine-4-carboxamide
- 81801-12-9
N
- 155774
- 538
- 137213
Y
- 7HE0JQL703
- D06328 Y
- ChEMBL75753 Y
- DTXSID8045222
- Interactive image
- O=C(NCCNCC(O)COc1ccc(O)cc1)N2CCOCC2
InChI
- InChI=1S/C16H25N3O5/c20-13-1-3-15(4-2-13)24-12-14(21)11-17-5-6-18-16(22)19-7-9-23-10-8-19/h1-4,14,17,20-21H,5-12H2,(H,18,22)Y
- Key:DXPOSRCHIDYWHW-UHFFFAOYSA-NY
N
Y (what is this?) (verify)Xamoterol is a cardiac stimulant. It works by binding to the β1 adrenergic receptor. It is a 3rd generation adrenergic β receptor partial agonist.[1] It provides cardiac stimulation at rest but it acts as a blocker during exercise.[2]
References
- ^ Marlow HF (1989). "Xamoterol, a beta 1-adrenoceptor partial agonist: review of the clinical efficacy in heart failure". British Journal of Clinical Pharmacology. 28 (Suppl 1): 23S–30S. doi:10.1111/j.1365-2125.1989.tb03570.x. PMC 1379873. PMID 2572251.
- ^ Rang HP, Dale MM, Ritter JM, Moore PK (1999). Pharmacology (5th ed.). Edinburgh; New York: Churchill Livingstone. p. 163. ISBN 0443059748.
- v
- t
- e
Adrenergic receptor modulators
- See also: Receptor/signaling modulators
- Dopaminergics
- Serotonergics
- Monoamine reuptake inhibitors
- Monoamine releasing agents
- Monoamine metabolism modulators
- Monoamine neurotoxins
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
